Kate Goodwin

Des Moines

Life Sciences Writer at BioSpace

christian. wife. mom. novelist. pharma news journalist. home buyer. renovator. professional mover. big talker. bigger dreams. indie author.

Featured in: Favicon

biospace.com Favicon

medium.com Favicon

calgaryherald.com Favicon

wallpaper.com Favicon

windsorstar.com Favicon

thestarphoenix.com Favicon

muskogeephoenix.com Favicon

architectureau.com Favicon

sec-ed.co.uk Favicon

invesbrain.com + 7 more

Articles

2025 Venice Architecture Biennale - Highlights

2 weeks ago | indesignlive.com | Kate Goodwin

This May, Venice has once again been swarmed with architects, curators and critics for the opening of the Venice Architecture Biennale, running through to the end of November. The 2025 curator, Carlo Ratti, has brought together over 720 participants making 300 contributions under his theme of Intelligens. Natural. Artificial. Collective.
Pittwater House School by Neeson Murcutt Neille

1 month ago | architectureau.com | Kate Goodwin

The twentieth century saw new developments, of varying quality, filling land and replacing older buildings in Australia’s cities to meet the demands of a growing population. While the pressure to accommodate growth continues, today’s environmental crisis requires a different approach that must work with these built legacies as the starting point.
Pittwater House School by Neeson Murcutt Neille

1 month ago | architectureau.com | Kate Goodwin

The twentieth century saw new developments, of varying quality, filling land and replacing older buildings in Australia’s cities to meet the demands of a growing population. While the pressure to accommodate growth continues, today’s environmental crisis requires a different approach that must work with these built legacies as the starting point.
Re-Stor(y)ing Oceania

2 months ago | architectureau.com | Kate Goodwin

On the shores of Gadigal waters in Sydney’s Woolloomooloo, the enchanting sound of a karanga – a Māori women’s spiritual call – fills the lobby of Artspace, welcoming visitors to Re-Stor(y)ing Oceania. The call sets the intention for the exhibition, which seeks to reconceptualise humanity’s relationship to the planet’s largest body of water at a time of an ecological, and arguably existential, crisis.
Gene Editing, Next-Gen Antibodies Key to Unlocking Animal-to-Human Transplants

2 months ago | biospace.com | Kate Goodwin

Breakthroughs in gene editing coupled with the next generation of anti-CD40L antibodies could help enable xenotransplantation—the transplantation of animal organs or tissues into humans—and provide a gateway to solving a major global health crisis: a shortage of donor organs. Each day, 20 people in the U.S. die waiting for an organ transplant.
GLP-1 Players Seek to Differentiate in Increasingly Crowded Weight Loss Space

2 months ago | biospace.com | Kate Goodwin

The rise of GLP-1 receptor agonists has changed the therapeutic weight loss industry forever. Now, as more companies jostle to join the lucrative market, touting the highest percentage weight loss may take a back seat to a different competitive edge: overall health outcomes. Certainly, the efficacy the market leaders boast has generated unprecedented demand.
GLP-1 Side Effects Only One Factor Driving Patient Discontinuation Rates

Mar 10, 2025 | biospace.com | Kate Goodwin

When GLP-1 drugs recently became a trendy talking point for their impressive weight loss efficacy, their less-than-appealing aspects also came into focus, particularly gastrointestinal side effects. Nausea, vomiting, diarrhea, constipation and abdominal pain are all commonly reported by people dropping pounds with Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound (tirzepatide).
Novo Enters the Ring in Legal Fight Against GLP-1 Compounders

Mar 6, 2025 | biospace.com | Kate Goodwin

The legal battle continues between the FDA and compounding pharmacies over the latter party’s ability to produce blockbuster weight loss drugs such as semaglutide—marketed by Novo Nordisk as Wegovy—and tirzepatide—marketed by Eli Lilly has Zepbound. Following the removal of these drugs from the FDA shortage list, the compounders trade group Outsourcing Facilities Association (OFA) filed lawsuits in an attempt to continue making the lucrative drugs.
FDA, Other Experts Seek to Redefine Obesity and Prioritize Maintenance Treatment

Mar 3, 2025 | biospace.com | Kate Goodwin

The World Health Organization has been sounding the alarm on obesity since the 1990s. Now, regulators and other leading experts are redefining the terms of the global obesity epidemic—with potential implications for patients, practitioners and drug developers.
Newly Stacked PhRMA to Meet With Trump on IRA, Other Policies

Feb 20, 2025 | biospace.com | Kate Goodwin

Leaders from the Pharmaceutical Research and Manufacturers of America will meet with President Trump on Thursday, and the drug industry’s largest lobbying group stacked the deck prior to the event. The purported fireside chat is an effort to work with the returning president on policies affecting drugmakers, according to Bloomberg, and the Pharmaceutical Research and Manufacturers of America (PhRMA) is hoping to undo some of the policies put in place during the Biden era.